Cargando…

BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer

The aberrant hypermethylation of BRCA1 promoter CpG islands induces the decreased expression of BRCA1 (Breast Cancer 1) protein. It can be detected in sporadic breast cancer without BRCA1 pathogenic variants, particularly in triple-negative breast cancers (TNBC). We investigated BRCA1 hypermethylati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jacot, William, Lopez-Crapez, Evelyne, Mollevi, Caroline, Boissière-Michot, Florence, Simony-Lafontaine, Joelle, Ho-Pun-Cheung, Alexandre, Chartron, Elodie, Theillet, Charles, Lemoine, Antoinette, Saffroy, Raphael, Lamy, Pierre-Jean, Guiu, Séverine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225997/ https://www.ncbi.nlm.nih.gov/pubmed/32235500 http://dx.doi.org/10.3390/cancers12040828

Ejemplares similares

Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers
por: Guiu, Séverine, et al.
Publicado: (2018)

Clinicopathological Correlates of γδ T Cell Infiltration in Triple-Negative Breast Cancer
por: Boissière-Michot, Florence, et al.
Publicado: (2021)

Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples
por: Ho-Pun-Cheung, Alexandre, et al.
Publicado: (2019)

Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival
por: Mansouri, Hanane, et al.
Publicado: (2020)

SPARC in cancer‐associated fibroblasts is an independent poor prognostic factor in non‐metastatic triple‐negative breast cancer and exhibits pro‐tumor activity
por: Alcaraz, Lindsay B., et al.
Publicado: (2022)

Association of CD206 Protein Expression with Immune Infiltration and Prognosis in Patients with Triple-Negative Breast Cancer
por: Bobrie, Angélique, et al.
Publicado: (2022)

Diversity of Tumor-Infiltrating, γδ T-Cell Abundance in Solid Cancers
por: Chabab, Ghita, et al.
Publicado: (2020)

Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers
por: Jacot, William, et al.
Publicado: (2021)

Reverse transcription-quantitative polymerase chain reaction: description of a RIN-based algorithm for accurate data normalization
por: Ho-Pun-Cheung, Alexandre, et al.
Publicado: (2009)

BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer
por: Jacot, William, et al.
Publicado: (2013)

CXCR2 Levels Correlate with Immune Infiltration and a Better Prognosis of Triple-Negative Breast Cancers
por: Boissière-Michot, Florence, et al.
Publicado: (2021)

Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer
por: Boissière-Michot, Florence, et al.
Publicado: (2022)

A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment
por: Alcaraz, Lindsay B, et al.
Publicado: (2021)

High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers
por: Jacot, William, et al.
Publicado: (2015)

BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib
por: Velazquez, Carolina, et al.
Publicado: (2023)

The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases
por: Darlix, Amélie, et al.
Publicado: (2019)

TOM1L1 drives membrane delivery of MT1-MMP to promote ERBB2-induced breast cancer cell invasion
por: Chevalier, Clément, et al.
Publicado: (2016)

Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles
por: Jacot, William, et al.
Publicado: (2011)

Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients
por: Darlix, Amélie, et al.
Publicado: (2016)

Prognostic Value of CXCR2 in Breast Cancer
por: Boissière-Michot, Florence, et al.
Publicado: (2020)

Hypermethylation of lncRNA MEG3 impairs chemosensitivity of breast cancer cells
por: Li, Hongchang, et al.
Publicado: (2020)

Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies
por: Ashraf, Yahya, et al.
Publicado: (2019)

Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review
por: Corbeau, Iléana, et al.
Publicado: (2020)

p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis
por: Lopez-Crapez, E, et al.
Publicado: (2005)

Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers
por: Glodzik, Dominik, et al.
Publicado: (2020)

BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells
por: Tassone, P, et al.
Publicado: (2003)

Loss of BRCA1 promotor hypermethylation in recurrent high-grade ovarian cancer
por: Prieske, Katharina, et al.
Publicado: (2017)

Identifying the BRCA1 c.-107A > T variant in Dutch patients with a tumor BRCA1 promoter hypermethylation
por: de Jong, Vincent M. T., et al.
Publicado: (2022)

The effects of BRCA1 expression on the chemosensitivity of gastric cancer cells to platinum agents
por: Kim, Geon, et al.
Publicado: (2019)

Quantification of HER Expression and Dimerization in Patients’ Tumor Samples Using Time-Resolved Förster Resonance Energy Transfer
por: Ho-Pun-Cheung, Alexandre, et al.
Publicado: (2012)

A Phase II Multicenter Trial on High-Dose Vitamin D Supplementation for the Correction of Vitamin D Insufficiency in Patients with Breast Cancer Receiving Adjuvant Chemotherapy
por: Chartron, Elodie, et al.
Publicado: (2021)

Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia
por: Scardocci, A, et al.
Publicado: (2006)

Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers
por: Lamy, Pierre-Jean, et al.
Publicado: (2011)

KRAS Mutation Detection in Paired Frozen and Formalin-Fixed Paraffin-Embedded (FFPE) Colorectal Cancer Tissues
por: Solassol, Jérome, et al.
Publicado: (2011)

Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse
por: du Manoir, Stanislas, et al.
Publicado: (2013)

Mitochondrial Roles and Cytoprotection in Chronic Liver Injury
por: Degli Esposti, Davide, et al.
Publicado: (2012)

BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer
por: Elazezy, Maha, et al.
Publicado: (2021)

BRCA1 promoter hypermethylation in sporadic epithelial ovarian carcinoma: Association with low expression of BRCA1, improved survival and co-expression of DNA methyltransferases
por: BAI, XUEFENG, et al.
Publicado: (2014)

Undetectable RAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With RAS-Mutant Metastatic Colorectal Cancer
por: Bouchahda, Mohamed, et al.
Publicado: (2020)

Inferring ligand-receptor cellular networks from bulk and spatial transcriptomic datasets with BulkSignalR
por: Villemin, Jean-Philippe, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2bdo1318ibk9top9rjge67pugd